Preetam Shah - Mar 11, 2024 Form 4 Insider Report for Cidara Therapeutics, Inc. (CDTX)

Role
CFO & CBO
Signature
/s/ Shane Ward, Attorney-in-Fact
Stock symbol
CDTX
Transactions as of
Mar 11, 2024
Transactions value $
-$12,680
Form type
4
Date filed
3/12/2024, 09:45 PM
Previous filing
Mar 29, 2023
Next filing
Mar 20, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CDTX Common Stock Sale -$12.7K -18.9K -7.69% $0.67 227K Mar 11, 2024 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.66 to $0.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F3 Includes 8,000 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan (ESPP) on May 19, 2023 and November 20, 2023.